Sex differences in COVID-19 mortality: opportunity to develop HSP27 (HSPB1) immunotherapy to treat hyper-inflammation?
作者信息
O'Brien Edward R, Sandhu Jagdeep K
机构信息
Division of Cardiology, Department of Cardiac Sciences, University of Calgary Cumming School of Medicine, Libin Cardiovascular Institute, HRIC GC68, 3280 Hospital Drive NW, Calgary, AB, T2N 4Z6, Canada.
Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa, ON, Canada.
出版信息
Cell Stress Chaperones. 2020 Sep;25(5):725-729. doi: 10.1007/s12192-020-01146-5. Epub 2020 Aug 6.
Abstract
摘要
相似文献
1
Sex differences in COVID-19 mortality: opportunity to develop HSP27 (HSPB1) immunotherapy to treat hyper-inflammation?
Cell Stress Chaperones. 2020 Sep;25(5):725-729. doi: 10.1007/s12192-020-01146-5. Epub 2020 Aug 6.
2
Targeting inflammation and cytokine storm in COVID-19.
Pharmacol Res. 2020 Sep;159:105051. doi: 10.1016/j.phrs.2020.105051. Epub 2020 Jun 27.
3
World War against COVID-19: How strong is our armamentarium?
Med J Malaysia. 2020 May;75(3):314-315.
4
Curing COVID-19.
Lancet Infect Dis. 2020 Oct;20(10):1101. doi: 10.1016/S1473-3099(20)30706-4. Epub 2020 Sep 10.
5
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
J Neurol Sci. 2020 May 15;412:116803. doi: 10.1016/j.jns.2020.116803. Epub 2020 Mar 25.
6
Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.
Indian J Pharmacol. 2020 Jan-Feb;52(1):1-5. doi: 10.4103/ijp.IJP_119_20. Epub 2020 Mar 11.
7
Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.
Front Immunol. 2020 May 19;11:1021. doi: 10.3389/fimmu.2020.01021. eCollection 2020.
8
Plea for multitargeted interventions for severe COVID-19.
Lancet Infect Dis. 2020 Oct;20(10):1122-1123. doi: 10.1016/S1473-3099(20)30312-1. Epub 2020 Apr 21.
9
The need to implement non-industry COVID-19 clinical trials in non-high-income countries.
J Glob Health. 2020 Jun;10(1):010351. doi: 10.7189/jogh.10.010351.
10
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
J Immunother Cancer. 2020 Apr;8(1). doi: 10.1136/jitc-2020-000878.
引用本文的文献
1
Unveiling the role of exercise in modulating plasma heat shock protein 27 levels: insights for exercise immunology and cardiovascular health.
Mol Cell Biochem. 2025 Mar;480(3):1381-1401. doi: 10.1007/s11010-024-05089-8. Epub 2024 Aug 22.
2
Phosphorylation of the small heat shock protein HspB1 regulates cytoskeletal recruitment and cell motility.
Mol Biol Cell. 2022 Sep 15;33(11):ar100. doi: 10.1091/mbc.E22-02-0057. Epub 2022 Jun 29.
3
Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies.
Cells. 2022 Jan 12;11(2):253. doi: 10.3390/cells11020253.
4
Updated pharmacological effects of Lonicerae japonicae flos, with a focus on its potential efficacy on coronavirus disease-2019 (COVID-19).
Curr Opin Pharmacol. 2021 Oct;60:200-207. doi: 10.1016/j.coph.2021.07.019. Epub 2021 Aug 10.
5
Sex-Related Overactivation of NLRP3 Inflammasome Increases Lethality of the Male COVID-19 Patients.
Front Mol Biosci. 2021 Jun 4;8:671363. doi: 10.3389/fmolb.2021.671363. eCollection 2021.
6
Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-κB: A Systematic Review.
Viruses. 2021 Feb 27;13(3):378. doi: 10.3390/v13030378.
7
Heat Shock Proteins in Oxidative Stress and Ischemia/Reperfusion Injury and Benefits from Physical Exercises: A Review to the Current Knowledge.
Oxid Med Cell Longev. 2021 Jan 31;2021:6678457. doi: 10.1155/2021/6678457. eCollection 2021.
8
Coronaviruses and stress: from cellular to global.
Cell Stress Chaperones. 2020 Sep;25(5):701-705. doi: 10.1007/s12192-020-01155-4. Epub 2020 Sep 5.
本文引用的文献
1
Heat shock protein 27 immune complex altered signaling and transport (ICAST): Novel mechanisms of attenuating inflammation.
FASEB J. 2020 Nov;34(11):14287-14301. doi: 10.1096/fj.202001389RR. Epub 2020 Sep 4.
2
Anakinra for severe forms of COVID-19: a cohort study.
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
3
Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation.
J Cardiovasc Transl Res. 2021 Feb;14(1):3-12. doi: 10.1007/s12265-020-10000-z. Epub 2020 Jul 13.
4
On barring the vascular gateway against severe COVID-19 disease.
Cell Stress Chaperones. 2020 Sep;25(5):721-723. doi: 10.1007/s12192-020-01122-z.
5
COVID-19: the vasculature unleashed.
Nat Rev Immunol. 2020 Jul;20(7):389-391. doi: 10.1038/s41577-020-0343-0.
6
Clinical trials for COVID-19 should include sex as a variable.
J Clin Invest. 2020 Jul 1;130(7):3350-3352. doi: 10.1172/JCI139306.
7
Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients.
J Pharm Pharm Sci. 2020;23(1):75-85. doi: 10.18433/jpps31069.
8
Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study.
BMJ. 2020 Apr 21;369:m1443. doi: 10.1136/bmj.m1443.
9
Clinical and immunological features of severe and moderate coronavirus disease 2019.
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
10
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.
Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.
Zotero 插件